ArticlePharmaceutics2020
Berberine-Loaded Liposomes for the Treatment of
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Lecithin-Coated PLGA Nanoparticles for Pulmonary Targeting of Naringin: Formulation, Optimization and In Vitro Characterization.International journal of molecular sciences · 2026Article
- Natural product-based therapeutic strategies againstFrontiers in microbiology · 2026Review
- Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advancing cancer therapy: Nanomaterial-based encapsulation strategies for enhanced delivery and efficacy of curcumin.Materials today. Bio · 2025Review
- Review
- Application of liposomal nanoparticles of berberine in photodynamic therapy of A549 lung cancer spheroids.Biochemistry and biophysics reports · 2024Article
- Enhancement of the stability and cytotoxicity of berberine by liposomal nanocarriers for gastric cancer treatment and its application in gummy candy.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Article
- The Prospects of Phytomedicines and Nanomedicines to Treat Leishmaniasis: A Comprehensive Review.Current drug research reviews · 2024Review
- Evaluation of the Antitumor Activity of Quaternary Ammonium Surfactants.International journal of molecular sciences · 2023Article
- Characterization ofAnimals : an open access journal from MDPI · 2023Article
- Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterization, and Evaluation.Pharmaceutics · 2023Article
- Lactoferrin modification of berberine nanoliposomes enhances the neuroprotective effects in a mouse model of Alzheimer's disease.Neural regeneration research · 2023Article
- Lipid Nanoparticles and Liposomes for Bone Diseases Treatment.Biomedicines · 2022Review
- Current Applications of Plant-Based Drug Delivery Nano Systems for Leishmaniasis Treatment.Pharmaceutics · 2022Review
- Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes with Charge Imparting Membrane Additives.Pharmaceutics · 2022Article
- Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.Molecules (Basel, Switzerland) · 2022Review
- Effect of topical berberine in murine cutaneous leishmaniasis lesions.The Journal of antimicrobial chemotherapy · 2022Article
- Discovery and Validation of Lmj_04_BRCT Domain, a Novel Therapeutic Target: Identification of Candidate Drugs for Leishmaniasis.International journal of molecular sciences · 2021Article
- Anticoccidial Activity of Berberine against Eimeria-Infected Chickens.The Korean journal of parasitology · 2021Article
- Green Approach: ''A Forwarding Step for Curing Leishmaniasis-A Neglected Tropical Disease''.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Berberine (BER)-an anti-inflammatory quaternary isoquinoline alkaloid extracted from plants-has been reported to have a variety of biologic properties, including antileishmanial activity. This work addresses the preparation of BER-loaded liposomes with the aim to prevent its rapid liver metabolism and improve the drug selective delivery to the infected organs in visceral leishmaniasis (VL). BER liposomes (LP-BER) displayed a mean size of 120 nm, negative Z-potential of -38 mV and loaded 6 nmol/μmol lipid. In vitro, the loading of BER in liposomes enhanced its selectivity index more than 7-fold by decreasing its cytotoxicity to macrophages. In mice, LP-BER enhanced drug accumulation in the liver and the spleen. Consequently, the liposomal delivery of the drug reduced parasite burden in the liver and spleen by three and one logarithms (99.2 and 93.5%), whereas the free drug only decreased the infection in the liver by 1-log. The organ drug concentrations-far from IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.